Drugs / Acasunlimab
Acasunlimab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04937153 | Jun 2021 → Oct 2024 | cancer | Genmab | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03917381 | May 2019 → Apr 2025 overdue | cancer | Genmab | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06984328 | Jul 2025 → May 2026 | cutaneous melanoma, metastatic melanoma | Genmab | Terminated | No outcome recorded |
| Phase 2 | NCT06046274 | Oct 2023 → Apr 2028 | endometrial cancer | Genmab | Withdrawn | No outcome recorded |
| Phase 2 | NCT05117242 | Oct 2021 → Dec 2024 overdue | non-small cell lung carcinoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06635824 | Nov 2024 → Jul 2027 expected | — | Genmab | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-01 | BioNTech SE | Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) biontech.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acasunlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04937153 ↗ |
| Known as | DuoBody PDL1x4-1BB | “acasunlimab (an experimental antibody also known as GEN1046 or DuoBody® PDL1x4-1BB)” NCT06635824 ↗ |
| Known as | GEN-1046 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095337 ↗ |
| Modality | Monoclonal antibody | “the bispecific antibody, acasunlimab (also known as GEN1046)” NCT06046274 ↗ |
| Route | Intravenous | “Acasunlimab will be administered intravenously once every 21 days” NCT03917381 ↗ |